RxDoctor Payments Data

Paul Davis, MD

Plastic and Reconstructive Surgery · Shreveport, LANPI 1306838552

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 28 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by AbbVie at 30.1% of the total. Reporting peaked in 2021 at $305 and has fallen 83.6% since, to $50 in 2025. That places this record below the midpoint for plastic and reconstructive surgery clinicians in LA, where the typical reported total is $2,109.

$655in general payments, 2019–2025

Across 28 payments — averaging $23.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$197
  • Sientra, Inc.$165
  • Sanara Medtech Inc.$134
  • Cardiovascular Systems Inc.$55
  • Silk Road Medical, Inc.$40
  • Abiomed$35
  • plus $29 from 2 others

What the payments were for

  • Food & beverage$655100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$655 in reported general payments places this provider in the 30th percentile of 45 plastic and reconstructive surgery providers in Louisiana.

See all plastic and reconstructive surgery providers in Louisiana

Medicare billing

Part B allowed, 2024
$41,595
Medicare patients
52
Services billed
156

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan12$7,935
Cephalexin24$119
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen21$108

Paid to pharmacies, not to this prescriber.

Other plastic and reconstructive surgery in Shreveport

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →